Carfilzomib + Dexamethasone
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Amyloidosis
Conditions
Amyloidosis, Systemic Light Chain Amyloidosis
Trial Timeline
Feb 1, 2013 → Jul 1, 2017
NCT ID
NCT01789242About Carfilzomib + Dexamethasone
Carfilzomib + Dexamethasone is a phase 1 stage product being developed by Amgen for Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01789242. Target conditions include Amyloidosis, Systemic Light Chain Amyloidosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02412878 | Phase 3 | Completed |
| NCT02257476 | Phase 1 | Completed |
| NCT01926665 | Phase 1 | Completed |
| NCT01789242 | Phase 1 | Completed |
| NCT01677858 | Phase 1/2 | Completed |
| NCT00531284 | Phase 1/2 | Completed |
| NCT00150462 | Phase 1 | Completed |
Competing Products
20 competing products in Amyloidosis